Influence of dosing schedule on organ exposure to cyclosporin in pediatric hematopoietic stem cell transplantation: analysis with a PBPK model.
OBJECTIVE
Cyclosporin is administered by intermittent infusions (II) or continuous infusions (CI) to prevent acute graft-versus-host disease (aGVHD). Because cyclosporin disposition is nonlinear, organ exposure may be higher after II than after CI, but saturation of receptors must be accounted for. The aim of the study was to compare both types of administration using a mechanistic model.


METHODS
A physiologically based pharmacokinetic model was developed to estimate cyclosporin exposure and receptor occupancies (RO) in aGVHD target organs and kidneys and to compare these estimations in pediatric patients that received cyclosporin either by II or CI. The relevant biological parameters were based on a clinical study in 2 groups of pediatric patients that received cyclosporin either by II (n = 31) or CI (n = 30).


RESULTS
Simulations showed that the exposure to cyclosporin in the interstitial fluid of aGVHD target organs was greater at day 1 after II than after CI. In kidneys, the opposite order was observed. AUC(RO) in all organs was greater after CI than after II. The therapeutic index (the ratio of AUC(RO) in blood to AUC(RO) in kidneys) was greater with CI than with II.


CONCLUSIONS
CI may be slightly more favorable than II for aGVHD prevention.
Gérard
Cécile
C
Université de Lyon, Lyon, France.
Bleyzac
Nathalie
N
Girard
Pascal
P
Freyer
Gilles
G
Bertrand
Yves
Y
Tod
Michel
M
D000818:Animals; D019540:Area Under Curve; D002648:Child; D016572:Cyclosporine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D051381:Rats; D012189:Retrospective Studies; D014018:Tissue Distribution
D016572:Cyclosporine
Ther Drug Monit. 2007 Dec;29(6):750-7
18043472
Clin Pharmacokinet. 2006;45(9):931-56
16928154
Ann Pharmacother. 1994 Mar;28(3):379-83
8193430
Bone Marrow Transplant. 1999 Sep;24(6):629-35
10490728
Br J Haematol. 1998 Jul;102(2):544-52
9695972
Clin Chim Acta. 2001 Nov;313(1-2):241-53
11694265
Annu Rev Immunol. 2007;25:139-70
17129175
Bone Marrow Transplant. 2003 Nov;32(9):881-7
14561988
Br J Clin Pharmacol. 2005 Jun;59(6):691-704
15948934
Clin Pharmacokinet. 2006;45(10):1013-34
16984214
Clin Chem. 2001 Sep;47(9):1679-87
11514403
Transplant Proc. 2004 Mar;36(2 Suppl):229S-233S
15041343
Pediatrics. 1992 Mar;89(3):495-501
1741227
Bone Marrow Transplant. 1997 Apr;19(8):759-64
9134165
Lancet. 2009 May 2;373(9674):1550-61
19282026
Curr Opin Nephrol Hypertens. 2002 Nov;11(6):619-26
12394607
Clin Biochem. 1991 Feb;24(1):81-7
2060137
J Pharmacokinet Biopharm. 1991 Feb;19(1):21-50
2023108
Annu Rev Pharmacol Toxicol. 2008;48:303-32
17914927
J Pharmacokinet Biopharm. 1999 Dec;27(6):597-623
11153448
Bone Marrow Transplant. 1998 Sep;22(6):541-5
9758340
Curr Drug Metab. 2002 Jun;3(3):275-87
12083321
Bone Marrow Transplant. 1995 May;15(5):663-8
7670393
Nature. 2001 May 17;411(6835):385-9
11357147
J Pharmacokinet Biopharm. 1994 Oct;22(5):327-65
7791036
Drug Metab Dispos. 1987 May-Jun;15(3):377-83
2886315
Bone Marrow Transplant. 2003 Oct;32(8):777-84
14520421
Ther Drug Monit. 1988;10(1):20-7
3287705
Bone Marrow Transplant. 2006 Oct;38(7):521-5
16981000
N Engl J Med. 1988 Jul 14;319(2):65-70
3288872
Clin Pharmacokinet. 2007;46(5):417-32
17465640
Clin Pharmacol Ther. 1999 Jul;66(1):66-75
10430111
Arch Pediatr. 2006 Jan;13(1):104-10
16257193
Biol Blood Marrow Transplant. 2009 Jun;15(6):741-8
19450759
Clin Chem. 1999 Sep;45(9):1477-84
10471650
Bone Marrow Transplant. 1991 Jun;7(6):461-5
1873593
J Pharmacol Exp Ther. 1998 Nov;287(2):457-68
9808668
Toxicol Ind Health. 1997 Jul-Aug;13(4):407-84
9249929